MARKET

ROIVW

ROIVW

Roivant Sciences
NASDAQ
2.020
+0.090
+4.66%
Closed 16:00 01/27 EST
OPEN
1.988
PREV CLOSE
1.930
HIGH
2.070
LOW
1.988
VOLUME
2.88K
TURNOVER
5.88K
52 WEEK HIGH
2.550
52 WEEK LOW
0.2181
MARKET CAP
--
P/E (TTM)
-1.1896
1D
5D
1M
3M
1Y
5Y
BRIEF-Roivant Announces Results From The Induction Period Of Phase 2B Study Of Subcutaneous Rvt-3101 For The Treatment Of Ulcerative Colitis
Reuters · 01/04 11:08
Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant
Edison Partners, a leading growth equity investment firm, today announced it is leading a $21 million investment round in Lokavant, the leading clinical trial intelligence company.
PR Newswire · 12/07/2022 11:30
Pfizer partners with Clear Creek Bio to develop oral COVID-19 drug
Reuters · 12/06/2022 13:40
UPDATE 1-Roivant, Pfizer launch unit to develop inflammatory disease drug
Reuters · 12/01/2022 13:33
BRIEF-Roivant Sciences Ltd - Expects That This Collaboration Will Not Impact Co’S Previously Announced Cash Runway Into Second Half Of Calendar Year 2025
Reuters · 12/01/2022 13:18
Roivant, Pfizer create unit for inflammatory disease drug
Reuters · 12/01/2022 13:12
BRIEF-Roivant Sciences Reports Financial Results For Q2
Reuters · 11/14/2022 13:09
BRIEF-Roivant Sciences Announces Pricing Of Primary And Secondary Public Equity Offering
Reuters · 11/08/2022 11:16
More
About ROIVW
Roivant Sciences Ltd. is a pharma company. The Company is focused on developing transformative medicines that address areas of unmet medical need. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The Company builds biotech and healthcare technology companies (Vants) and deploys technology to drive research and development and commercialization. The Company’s product candidate includes VTAMA (tapinarof), IMVT-1401, Brepocitinib, Namilumab and RVT-2001. Its Vant family includes Dermavant, Immunovant, Priovant, Kinevant and Hemavant. Its small molecule discovery engine is powered by computational physics and machine learning (ML) capabilities for in silico drug design. The Company’s capabilities in diverse therapeutic areas, including immunology, dermatology and oncology, and modalities, including biologics, topicals and bifunctional small molecules.

Webull offers kinds of Roivant Sciences Ltd stock information, including NASDAQ:ROIVW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ROIVW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ROIVW stock methods without spending real money on the virtual paper trading platform.